Skip to main content
Skip to navigation
Research Exchange
Living Lab
Discovery Lab
Donate
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk
Peter A. Fasching
· 2025-03-22
Links
DOI
PubMed
Journal
The Breast
Institutions
Universittsklinikum Erlangen
Authors
Peter A. Fasching
Funding
Novartis Funding
Novartis Pharma GmbH Funding